Merck starts final-stage trial of lung cancer drug combination
Merck & Co. (NYSE:MRK) began a late-stage clinical trial for a new combination therapy aimed at untreated lung cancer, seeking to eliminate the need for traditional chemotherapy and intravenous infusions for patients with a specific genetic mutation.


















-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)

